EUVIMEDEUVIMED entdecken
Crossref

LncRNA TRAF3IP2 ‐ AS1 Serves as a Potential Biomarker and Drives Acute Myeloid Leukemia Progression via miR ‐186‐5p/ EP300 Axis

Jifei Dai, Mingya Yang, Min Ruan, Ruixiang Xia iD

International Journal of Laboratory Hematology · 04.11.2026

DOI: 10.1111/ijlh.70264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, online erschienen am 04.11.2026. Verfasst von Jifei Dai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the expression, clinical significance, and biological function of lncRNA TRAF3IP2‐AS1 in acute myeloid leukemia (AML) and to elucidate its underlying molecular mechanisms.

Methods

The levels of TRAF3IP2‐AS1, miR‐186‐5p, and EP300 were detected by RT‐qPCR from 132 patients with AML and 130 healthy controls, as well as in AML cell lines. Bioinformatics analysis, dual‐luciferase reporter assays, RIP assays, and other experiments were performed to validate the TRAF3IP2‐AS1/miR‐186‐5p/EP300 regulatory axis. Cell proliferation, apoptosis, and cell cycle were assessed by CCK‐8, flow cytometry, and RT‐qPCR.

Results

TRAF3IP2‐AS1 was upregulated in AML patient samples and cell lines. TRAF3IP2‐AS1 had good diagnostic efficacy for AML (AUC = 0.909) and was an independent prognostic risk factor for poor prognosis of AML patients. Functional experiments confirmed that silencing TRAF3IP2‐AS1 significantly inhibited AML cell proliferation, induced apoptosis, and caused G1 phase arrest. Mechanistically, TRAF3IP2‐AS1 acted as a ceRNA to sponge miR‐186‐5p, thereby relieving its inhibitory effect on the downstream target gene EP300, and ultimately promoting the malignant biological behavior of AML cells.

Conclusion

TRAF3IP2‐AS1 promotes AML progression through the miR‐186‐5p/EP300 axis and represents a potential diagnostic biomarker, prognostic indicator, and therapeutic target for AML.

Schlagwörter

Stichwörter der Autor:innen

EP300TRAF3IP2‐AS1acute myeloid leukemiadiagnosismiR‐186‐5p

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Anhui Zhongke Gengjiu Hospital, Hefei, China.

ORCID-Profile: Ruixiang Xia

Zitieren

APA

Dai, J., Yang, M., Ruan, M., & Xia, R. (2026). LncRNA TRAF3IP2 ‐ AS1 Serves as a Potential Biomarker and Drives Acute Myeloid Leukemia Progression via miR ‐186‐5p/ EP300 Axis. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.70264

Vancouver

Dai J, Yang M, Ruan M, Xia R. LncRNA TRAF3IP2 ‐ AS1 Serves as a Potential Biomarker and Drives Acute Myeloid Leukemia Progression via miR ‐186‐5p/ EP300 Axis. International Journal of Laboratory Hematology. 2026. doi:10.1111/ijlh.70264

BibTeX
@article{Dai2026,
  author = {Dai, Jifei and Yang, Mingya and Ruan, Min and Xia, Ruixiang},
  title = {LncRNA TRAF3IP2 ‐ AS1 Serves as a Potential Biomarker and Drives Acute Myeloid Leukemia Progression via miR ‐186‐5p/ EP300 Axis},
  journal = {International Journal of Laboratory Hematology},
  year = {2026},
  doi = {10.1111/ijlh.70264}
}
Kostenlos starten →